Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Pacira BioSciences	Organogenesis	Deciphera Pharmaceuticals	Rocket Pharmaceuticals	Corcept Therapeutics
Symbol	NASDAQ:PCRX	NASDAQ:ORGO	NASDAQ:DCPH	NASDAQ:RCKT	NASDAQ:CORT
Price Information
Current Price	$62.45	$17.44	$33.74	$41.31	$20.83
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	2.3	1.0	1.6	1.4	1.7
Analysis Score	4.3	1.5	3.4	3.5	2.3
Community Score	2.9	2.6	2.5	2.9	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.8	1.7	0.8	1.7
Earnings & Valuation Score	4.4	0.0	0.6	0.0	1.9
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$78.58	$17.50	$73.00	$59.18	$24.00
% Upside from Price Target	25.83% upside	0.34% upside	116.36% upside	43.26% upside	15.22% upside
Trade Information
Market Cap	$2.67 billion	$2.30 billion	$1.94 billion	$2.60 billion	$2.39 billion
Beta	1.27	1.84	1.49	2.05	1.04
Average Volume	476,391	827,913	454,639	497,800	569,850
Sales & Book Value
Annual Revenue	$421.03 million	$260.98 million	$25 million	N/A	$306.49 million
Price / Sales	6.53	8.57	78.23	N/A	7.93
Cashflow	$1.47 per share	N/A	N/A	N/A	$0.63 per share
Price / Cash	42.56	N/A	N/A	N/A	33.26
Book Value	$8.51 per share	$0.59 per share	$10.71 per share	$6.10 per share	$3.25 per share
Price / Book	7.34	29.56	3.15	N/A	6.41
Profitability
Net Income	$-11,020,000.00	$-40,450,000.00	$-192,260,000.00	$-77,270,000.00	$94.18 million
EPS	$0.86	($0.42)	($4.48)	($1.58)	$0.77
Trailing P/E Ratio	21.99	N/A	N/A	N/A	23.40
Forward P/E Ratio	21.68	N/A	N/A	N/A	22.64
P/E Growth	0.82	N/A	N/A	N/A	N/A
Net Margins	29.95%	-1.61%	N/A	N/A	30.73%
Return on Equity (ROE)	10.71%	-10.03%	-45.02%	-35.81%	25.38%
Return on Assets (ROA)	4.88%	-2.22%	-40.12%	-27.52%	23.16%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.78%	1.54%	N/A	0.25%	N/A
Current Ratio	7.63%	1.95%	9.34%	7.30%	10.77%
Quick Ratio	6.84%	1.50%	9.26%	7.30%	10.65%
Ownership Information
Institutional Ownership Percentage	N/A	4.62%	73.61%	N/A	75.44%
Insider Ownership Percentage	5.80%	57.20%	7.02%	41.40%	16.40%
Miscellaneous
Employees	624	910	350	91	236
Shares Outstanding	44.03 million	128.21 million	57.96 million	61.78 million	116.63 million
Next Earnings Date	8/5/2021 (Estimated)	8/9/2021 (Estimated)	8/3/2021 (Estimated)	8/4/2021 (Estimated)	8/3/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Optionable	Optionable

Source	Headline
	Corcept Therapeutics (NASDAQ:CORT) Announces Earnings Results americanbankingnews.com - May 9 at 12:58 PM
	Corcept Therapeutics Incorporated (NASDAQ:CORT) Is an Exciting Stock stocksregister.com - May 8 at 7:37 PM
	Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y nasdaq.com - May 7 at 1:38 PM
	Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates finance.yahoo.com - May 6 at 10:36 PM
	Corcept: Q1 Earnings Snapshot \| Raleigh News & Observer newsobserver.com - May 6 at 5:36 PM
	Corcept: Q1 Earnings Snapshot sfgate.com - May 6 at 5:36 PM
	Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer finance.yahoo.com - May 6 at 5:36 PM
	Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH) finance.yahoo.com - May 6 at 5:36 PM
	Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results finance.yahoo.com - May 6 at 5:36 PM
	Corcept Therapeutics Stock Is Believed To Be Modestly Overvalued ca.finance.yahoo.com - May 5 at 9:34 PM
	Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy? finance.yahoo.com - May 5 at 11:33 AM
	CORT Crosses Below Key Moving Average Level nasdaq.com - May 4 at 2:06 PM
	Reviewing Corcept Therapeutics (NASDAQ:CORT) and Intec Pharma (NASDAQ:NTEC) americanbankingnews.com - May 4 at 12:14 AM
	Earnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to Decline finance.yahoo.com - April 26 at 1:55 PM
	Imagine Holding Corcept Therapeutics (NASDAQ:CORT) Shares While The Price Zoomed 398% Higher finance.yahoo.com - April 5 at 8:06 AM
	Why Is Corcept (CORT) Down 11.1% Since Last Earnings Report? finance.yahoo.com - March 25 at 12:29 PM
	Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant finance.yahoo.com - March 16 at 1:45 PM
	Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in ... apnews.com - March 15 at 12:36 PM
	Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess finance.yahoo.com - March 15 at 7:35 AM
	Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; apnews.com - March 1 at 8:00 PM
	Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer finance.yahoo.com - March 1 at 8:00 PM
	Corcept (CORT) Q4 Earnings In Line, Revenues Miss Estimates nasdaq.com - February 24 at 1:44 PM
	Corcept: 4Q Earnings Snapshot \| Raleigh News & Observer newsobserver.com - February 23 at 7:32 PM
	Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results finance.yahoo.com - February 23 at 7:32 PM
	Trade Alert: The CFO & Secretary Of Corcept Therapeutics Incorporated (NASDAQ:CORT), Gary Robb, Has Sold Some Shares Recently nasdaq.com - February 21 at 8:55 AM

Date	Company	Brokerage	Action
5/11/2021	Pacira BioSciences	Northland Securities	Lower Price Target
5/10/2021	Pacira BioSciences	BMO Capital Markets	Lower Price Target
4/15/2021	Pacira BioSciences	Berenberg Bank	Initiated Coverage
3/8/2021	Pacira BioSciences	HC Wainwright	Boost Price Target
2/26/2021	Pacira BioSciences	Barclays	Boost Price Target
1/21/2021	Pacira BioSciences	SVB Leerink	Downgrade
1/20/2021	Pacira BioSciences	Piper Sandler	Boost Price Target
1/8/2021	Pacira BioSciences	Needham & Company LLC	Boost Price Target
1/6/2021	Pacira BioSciences	Royal Bank of Canada	Boost Price Target
11/2/2020	Pacira BioSciences	Wedbush	Lower Price Target
9/30/2020	Pacira BioSciences	Jefferies Financial Group	Boost Price Target
8/14/2020	Pacira BioSciences	Truist	Boost Price Target
3/12/2021	Organogenesis	Credit Suisse Group	Boost Price Target
1/14/2021	Organogenesis	BTIG Research	Boost Price Target
9/21/2020	Organogenesis	Oppenheimer	Reiterated Rating
12/2/2020	Deciphera Pharmaceuticals	Stifel Nicolaus	Initiated Coverage
9/14/2020	Deciphera Pharmaceuticals	JPMorgan Chase & Co.	Initiated Coverage
6/12/2020	Deciphera Pharmaceuticals	Guggenheim	Reiterated Rating
5/18/2020	Deciphera Pharmaceuticals	SunTrust Banks	Boost Price Target
5/7/2020	Deciphera Pharmaceuticals	Nomura Instinet	Downgrade
1/21/2020	Deciphera Pharmaceuticals	Nomura Securities	Boost Price Target
1/15/2020	Deciphera Pharmaceuticals	JMP Securities	Reiterated Rating
12/15/2020	Rocket Pharmaceuticals	UBS Group	Initiated Coverage
12/10/2020	Rocket Pharmaceuticals	Evercore ISI	Boost Price Target
12/8/2020	Rocket Pharmaceuticals	Chardan Capital	Boost Price Target
10/16/2020	Rocket Pharmaceuticals	Lifesci Capital	Reiterated Rating
8/9/2020	Rocket Pharmaceuticals	Cowen	Reiterated Rating
8/5/2020	Rocket Pharmaceuticals	Ci Capital	Reiterated Rating
6/25/2020	Rocket Pharmaceuticals	Bank of America	Initiated Coverage
5/6/2020	Rocket Pharmaceuticals	William Blair	Reiterated Rating
2/21/2020	Corcept Therapeutics	Cantor Fitzgerald	Reiterated Rating
2/5/2019	Corcept Therapeutics	B. Riley	Set Price Target

(Data available from 5/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources